NEA led a $100m Series A round in Amber Therapeutics.

NEA, an American-based venture capital firm, led a $100m Series A round in Amber Therapeutics, a UK-based medical technology company developing a breakthrough adaptive neuromodulation therapy to treat mixed urinary incontinence, with participation from Oxford Science Enterprises, F-Prime Capital, Lightstone Ventures, Intuitive Ventures, and 8VC. “We believe Amber Therapeutics has the potential to become the first ever approved therapy for a significantly under-addressed patient population. This technology is the culmination of decades of research, and we are proud to support such an innovative therapy that could provide an effective treatment for an often overlooked and under-discussed condition that affects so many women worldwide,” Tiffany Le, NEA Principal.